Xiamen Amoytop Biotech Co., Ltd.

Xiamen Amoytop Biotech Co., Ltd. is an innovative Chinese biopharmaceutical company headquartered in Xiamen, Fujian Province. Founded in 1996, the company specializes in the research, development, manufacturing, and marketing of recombinant protein drugs, with a strong focus on immune-related cytokine medicines and long-acting PEGylated protein therapeutics. Amoytop is a publicly listed company on the Shanghai Stock Exchange STAR Market (Ticker: 688278.SS). Its strategic priority is achieving functional cures for chronic hepatitis B (CHB) through combination therapies, while also maintaining a robust portfolio in oncology, hematology, and immunology. The company operates a comprehensive R&D and manufacturing system, including national-level postdoctoral research stations, and has established itself as a leader in the field of PEGylated protein drugs in China.